CLL study: FCR+ABT-263 vs. BR+ABT263

[Guest guest]

Study of ABT-263 With Fludarabine/Cyclophosphamide/Rituximab OR With

Bendamustine/Rituximab in Relapsed or Refractory CLL

Must have relapsed or refractory CLL, received no more than 5 prior

treatments and must be a candidate for treatment with either FCR or BR

http://bit.ly/cmWi5x

" ABT-263 is a novel, orally bioavailable and active small molecule Bcl-2

family protein inhibitor that shows early evidence of activity in lymphoid

malignancies. "

http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/8511

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Non-profit | Independent | Evidence-based

www.lymphomation.org | Current News: http://bit.ly/f2A0T

How to Help: www.lymphomation.org/how-to-help.htm